Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout

Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases. Read why I rate NKTR stock a ...
Healio

Most patients with CRSwNP stop using oral corticosteroids after starting dupilumab

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, according to data presented at the American College of Allergy, Asthma & ...
BioSpace

Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives ...

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...
BioSpace

Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
TipRanks on MSN

Regeneron initiated with a Sector Perform at Scotiabank

Scotiabank analyst Louise Chen initiated coverage of Regeneron (REGN) with a Sector Perform rating and $650 price target Published first on TheFly ...
Dividend Power

3 Top Dividend Stocks to Buy in the Fall of 2025

In this article, we will discuss 3 top dividend stocks with yields above 4% that could be attractive buys in the fall of 2025 ...